Abstract
Osteoarthritis is characterised by degeneration of articular cartilage. It is thought to be primarily a disease of cartilage. Inflammatory response genes, such as proteinases, cyclooxygenase, and cytokines are implicated in its pathogenesis. The evidence for expression of these genes in articular cartilage in osteoarthritis is reviewed. The expression of inflammatory response genes is controlled by four major intracellular signalling pathways. These lead to activation of the three mitogen-activated protein kinases (MAPK) and the transcriptional regulator nuclear factor kappa (NFκ )-B. The current state of knowledge of the structure of these pathways is summarized. Pharmacological inhibitors of the protein kinases of the pathways in current use are described, and insights into chondrocyte gene expression obtained with them are discussed. Very limited use of these inhibitors has yet been made in animal models of osteoarthritis. The main use of the inhibitors in the near future will be in investigation of pathogenetic mechanisms in osteoarthritis, both in experimental animals and in vitro, with a view to identifying therapeutic targets. Prospects for using signalling pathway inhibitors for therapy in osteoarthritis are distant.
Keywords: Chondrocyte, MAP kinase, NF-κ B, matrix metalloproteinase, protein kinase, protein kinase inhibitor, inflammatory response, osteoarthritis
Current Drug Targets
Title: Inflammatory Signaling in Cartilage: MAPK and NF-κ B Pathways in Chondrocytes and the Use of Inhibitors for Research into Pathogenesis and Therapy of Osteoarthritis
Volume: 8 Issue: 2
Author(s): Jeremy Saklatvala
Affiliation:
Keywords: Chondrocyte, MAP kinase, NF-κ B, matrix metalloproteinase, protein kinase, protein kinase inhibitor, inflammatory response, osteoarthritis
Abstract: Osteoarthritis is characterised by degeneration of articular cartilage. It is thought to be primarily a disease of cartilage. Inflammatory response genes, such as proteinases, cyclooxygenase, and cytokines are implicated in its pathogenesis. The evidence for expression of these genes in articular cartilage in osteoarthritis is reviewed. The expression of inflammatory response genes is controlled by four major intracellular signalling pathways. These lead to activation of the three mitogen-activated protein kinases (MAPK) and the transcriptional regulator nuclear factor kappa (NFκ )-B. The current state of knowledge of the structure of these pathways is summarized. Pharmacological inhibitors of the protein kinases of the pathways in current use are described, and insights into chondrocyte gene expression obtained with them are discussed. Very limited use of these inhibitors has yet been made in animal models of osteoarthritis. The main use of the inhibitors in the near future will be in investigation of pathogenetic mechanisms in osteoarthritis, both in experimental animals and in vitro, with a view to identifying therapeutic targets. Prospects for using signalling pathway inhibitors for therapy in osteoarthritis are distant.
Export Options
About this article
Cite this article as:
Saklatvala Jeremy, Inflammatory Signaling in Cartilage: MAPK and NF-κ B Pathways in Chondrocytes and the Use of Inhibitors for Research into Pathogenesis and Therapy of Osteoarthritis, Current Drug Targets 2007; 8 (2) . https://dx.doi.org/10.2174/138945007779940115
DOI https://dx.doi.org/10.2174/138945007779940115 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery The Role of MDCT in Craniocervical Junction Pathologies: Pictorial Review
Current Medical Imaging Cordycepin Affects Multiple Apoptotic Pathways to Mediate Hepatocellular Carcinoma Cell Death
Anti-Cancer Agents in Medicinal Chemistry Allelic Imbalances of the egfr Gene as Key Events in Breast Cancer Progression – the Concept of Committed Progenitor Cells
Current Cancer Drug Targets MicroRNA-96 is Downregulated in Sepsis Neonates and Attenuates LPSInduced Inflammatory Response by Inhibiting IL-16 in Monocytes
Combinatorial Chemistry & High Throughput Screening Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Dose-Intensive Chemotherapy with Stem Cell Support as a Treatment Strategy for Bone and Soft-Tissue Sarcomas
Current Stem Cell Research & Therapy Aggrecanase: The Family and Its Inhibitors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Update on Targets of Biologic Therapies for Rheumatoid Arthritis
Current Rheumatology Reviews Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets